Clinical Trial Update: Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial is investigating tislelizumab in combination with Huaier granule as first-line therapy for unresectable hepatocellular carcinoma (HCC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Huaier Granule
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Tongji Hospital | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2 | Status: RECRUITING